coArtHA试验:撒哈拉以南非洲高血压治疗策略随机对照试验方案
该试验为开放标签三臂平行随机对照试验,在莱索托和坦桑尼亚两家农村医院比较三种降压策略在≥18岁未治疗无并发症高血压患者中的疗效与成本效果,样本量1268例,主要终点为12周血压达标比例。
要点
- 比较三联低剂量联合方案与现行标准治疗(单药后双药)的优效性。
- 比较双药联合方案与标准治疗的非劣效性,必要时4周和8周滴定。
- 主要终点为12周血压达标比例,<65岁目标≤130/80 mmHg,≥65岁≤140/90 mmHg。
核心结论
- 该试验旨在识别撒哈拉以南非洲农村非洲裔无并发症高血压患者中最有效且具成本效益的治疗策略,并为区域指南提供依据。
研究设计与样本
- 开放标签、三臂、平行随机对照试验,在莱索托和坦桑尼亚两家农村医院开展。
- 纳入≥18岁、标准化诊室血压≥140/90 mmHg的未治疗无并发症高血压患者。
- 样本量1268例,双药、三联和对照臂按2:1:2比例平行随机分配。
关键数值与推荐
- 主要终点为12周血压达标比例:<65岁目标≤130/80 mmHg,≥65岁目标≤140/90 mmHg。
- 双药联合方案与标准治疗进行非劣效比较,未达标者在4周和8周可选剂量滴定。
- 三联低剂量联合方案与现行标准治疗(单药后双药)进行优效性比较。
- 次要终点包括6个月时靶器官损害的临床表现和成本效果。
临床怎么用
- 试验结果预期为撒哈拉以南非洲农村非洲裔无并发症高血压的降压管理提供策略选择依据。
- 结果将用于指导该地区未来高血压管理临床指南的制定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Arterial hypertension is the most prevalent risk factor for cardiovascular disease in sub-Saharan Africa. Only a few and mostly small randomized trials have studied antihypertensive treatments in people of African descent living in sub-Saharan Africa. METHODS: In this open-label, three-arm, parallel randomized controlled trial conducted at two rural hospitals in Lesotho and Tanzania, we compare the efficacy and cost-effectiveness of three antihypertensive treatment strategies among participants aged ≥ 18 years. The study includes patients with untreated uncomplicated arterial hypertension diagnosed by a standardized office blood pressure ≥ 140/90 mmHg. The trial encompasses a superiority comparison between a triple low-dose antihypertensive drug combination versus the current standard of care (monotherapy followed by dual treatment), as well as a non-inferiority comparison for a dual drug combination versus standard of care with optional dose titration after 4 and 8 weeks for participants not reaching the target blood pressure. The sample size is 1268 participants with parallel allocation and a randomization ratio of 2:1:2 for the dual, triple and control arms, respectively. The primary endpoint is the proportion of participants reaching a target blood pressure at 12 weeks of ≤ 130/80 mmHg and ≤ 140/90 mmHg among those aged < 65 years and ≥ 65 years, respectively. Clinical manifestations of end-organ damage and cost-effectiveness at 6 months are secondary endpoints. DISCUSSION: This trial will help to identify the most effective and cost-effective treatment strategies for uncomplicated arterial hypertension among people of African descent living in rural sub-Saharan Africa and inform future clinical guidelines on antihypertensive management in the region. TRIAL REGISTRATION: Clinicaltrials.gov NCT04129840 . Registered on 17 October 2019 ( https://www.clinicaltrials.gov/ ).
引用
- Mapesi H, Gupta R, Wilson HI, et al. The coArtHA trial-identifying the most effective treatment strategies to control arterial hypertension in sub-Saharan Africa: study protocol for a randomized controlled trial. Trials. 2021. PMID: 33478567. doi:10.1186/s13063-021-05023-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。